Table 3. Efficacy data in different lines of treatment.
| Parameters | 1st line CTx+ICI | 2nd line R+D | 3rd line | ||
| N=77 | N=77 | N=20 | |||
| Number of cycles; mean (95% CI) | 9.0 (7.4–10.6) | 6.0 (5.1–7.0) | – | ||
| Of those | |||||
| Maintenance CTx+ICI | 2.0 (1.2–2.8) | 2.1 (1.3–3.0) | |||
| Maintenance ICI mono | 3.5 (2.0–5.0) | ||||
| Ramucirumab mono | – | ||||
| ORR; N (%) | |||||
| CR | 3 (3.9) | ||||
| PR | 36 (46.8) | 25 (32.5) | 2 (2.6) | ||
| SD | 23 (29.9) | 23 (29.9) | 4 (5.2) | ||
| PD | 15 (19.5) | 23 (29.9) | 8 (10.4) | ||
| n.r. | – | 6 (7.8) | 6 (7.8) | ||
| 2nd line ongoing 15 (19.5); no further therapy 42 (54.5) |
|||||
| DOR; median (95% CI) | 8.7 (6.3–11.0) | 6.4 (5.4–7.4) | – | ||
| PFS; median (95% CI) (months) | 5.8 (5.0–6.6) | 3.9 (3.1–4.6) | – | ||
| PFS according to subgroups | |||||
| Histology | |||||
| Adenocarcinoma | 6.0 (5.0–7.0) | 3.9 (3.0–4.8) | – | ||
| Squamous cell carcinoma | 5.6 (5.0–6.2) | 4.4 (2.3–6.4) | – | ||
| PD-L1 | |||||
| TPS <1% | 4.8 (3.7–6.0) | 3.5 (2.6–4.5) | – | ||
| TPS 1–49% | 6.0 (5.6–6.4) | 5.1 (3.1–7.1) | – | ||
| TPS ≥50% | 7.2 (7.1–7.3) | 12.3 (2.5–22.0) | – | ||
| KRAS | |||||
| Wild-type | 6.0 (4.8–7.2) | 4.5 (2.6–6.4) | – | ||
| Mutated | 4.8 (3.2–6.3) | 2.8 (1.7–3.9) | – | ||
| OS from line of thx; median (95%CI) (months) | 15.5 (12.2–18.9) | 7.5 (5.1–10.0) | 3.4 (2.6–4.2) |
TPS, tumor proportional score on immunohistochemistry; DOR, duration of response.